MedTrace Logo

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

NCT01357668 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2025-09-25

No results posted yet for this study

Summary

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Conditions

  • Juvenile Idiopathic Arthritis

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-30
Primary Completion
2029-01-02
Completion
2029-01-02

Countries

  • United States
  • Austria
  • Brazil
  • Canada
  • Denmark
  • France
  • Germany
  • Greece
  • Hungary
  • Israel
  • Italy
  • Latvia
  • Mexico
  • Netherlands
  • Norway
  • Peru
  • Portugal
  • Puerto Rico
  • Romania
  • Russia
  • Saudi Arabia
  • Slovakia
  • South Africa
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01357668 on ClinicalTrials.gov